# Microplastics Dose Metrics and Measurement Uncertainty > Particle counts and polymer mass are not interchangeable. Cox intake models are lower bounds vs nano-era methods. The credit-card-per-week claim fails error analysis. *Published 2026-07-10 · Updated 2026-07-10 · By Elena Voss* In short Dose comes as **counts or mass**—not interchangeable. Cox: ~**39–52k**/year diet, ~**74–121k** with inhalation. **Credit-card/week is false** (Pletz). Nano methods raise water counts. Agencies: data gaps, not proven population risk at measured levels. Viral mass memes and careful intake models are not the same genre of number. Label the genre before the headline. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What are the foundational intake estimates? [Cox et al. 2019](https://pubs.acs.org/doi/10.1021/acs.est.9b01517) remains the widely cited U.S. intake model for particle counts from evaluated foods and air. Age and sex gradients appear because intake rates and assumptions differ. Model-boundary tagging matters: only a fraction of calories was covered. Nano-era uplift notes are mandatory when citing pre-2024 water and food counts that missed most nanoplastics. Dual-metric reporting pairs counts and mass when both exist and refuses to average them into nonsense composites. ## Why did the credit-card meme fail? [Pletz 2022](https://www.sciencedirect.com/science/article/pii/S2666911022000247) documents severe calculation errors behind weekly mass claims near five grams. Error-prone unit conversions and non-representative extrapolations created a sticky false quantitative norm. Responsible communication rejects the meme even while taking real exposure seriously. Uncertainty stacks include incomplete inventories, nano undercount, lab contamination, no agreed toxicologically relevant dose metric, particle versus additive confusion, and animal-to-human extrapolation problems. Dose communication anchors MetricFigure / stance Cox diet particles/year~39–52k Cox diet+inhalation/year~74–121k Qian bottled water~2.4×10⁵ particles/L mean Credit-card/week massNot supported (Pletz) FDA foods stanceRisk not demonstrated at detected levels ## How should tissue burdens and agency language be handled? Tissue polymer mass in organs is not the same as weekly packaging eaten. Illustrative mass equivalents in media need caution labels. Exposure estimates, tissue burdens, and clinical risk are three different claims. [FDA](https://www.fda.gov/food/environmental-contaminants-food/microplastics-and-nanoplastics-foods) and WHO postures emphasize data gaps and insufficient demonstration of risk at measured food and water levels while research continues. Chartres-style suspected hazards are not proven population attributable fractions. Align risk language carefully. ## What anti-patterns should editors refuse? Headlining credit-card ingestion as fact. Summing incompatible particle-size studies into one average intake. Equating micrograms of polymer per gram of brain with you ate X grams of packaging. Claiming safe or toxic at population level without dose-response. Ignoring inhalation when only discussing food. Prefer primary units as published. Label Cox as lower-bound versus nano methods. See also [Qian 2024](https://www.pnas.org/doi/10.1073/pnas.2300582121) for why bottled-water dose assumptions moved when methods improved. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. ## Sources 1. [Cox 2019 intake estimates](https://pubs.acs.org/doi/10.1021/acs.est.9b01517) 2. [Pletz 2022 credit-card critique](https://www.sciencedirect.com/science/article/pii/S2666911022000247) 3. [Qian 2024 bottled water nanoplastics](https://www.pnas.org/doi/10.1073/pnas.2300582121) 4. [FDA MNPs in foods](https://www.fda.gov/food/environmental-contaminants-food/microplastics-and-nanoplastics-foods) 5. [WHO 2019 drinking-water MPs](https://www.who.int/publications/i/item/9789241516198) --- Source: https://healthcanon.com/environmental-health/microplastics-dose-metrics-uncertainty Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt